You are here

Development of a T cell-targeted TGF-b antagonist that reverses immune suppression in melanoma patients

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43CA232800-01
Agency Tracking Number: R43CA232800
Amount: $299,946.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: 102
Solicitation Number: PA17-302
Solicitation Year: 2017
Award Year: 2018
Award Start Date (Proposal Award Date): 2018-09-14
Award End Date (Contract End Date): 2019-08-31
Small Business Information
New York, NY 10038-2510
United States
DUNS: 080307848
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 (917) 837-8796
Business Contact
Phone: (917) 837-8796
Research Institution

PROJECT SUMMARY ABSTRACT SYNTHIS SBIR PH ISynthisLLC is an early stageNew York based biotech company developing a novel immuno oncologyIOtherapeutic to treat metastatic melanoma patientsThe immune checkpoint inhibitorsanti PDPDLare
first line therapies for melanomabut the majority of these patientsare not responsiveleaving a large
unmet need in this cancer populationTGFis a pro tumorigenic cytokine that drives cancer developmentin
partby promoting angiogenesisdriving epithelial to mesenchymal transition and suppressing the immune
systemGeneral TGFantagonists have been developed as cancer therapeuticsbut have two serious
issuesserious host tissue toxicity due to broad TGFreceptor expression on normal tissues andpotential to increase tumor development due to paradoxical effects on the tumor and surrounding
microenvironmentTogetherthis has led to a small therapeutic window for TGFantagonists and limited
patient responsesTo bypass these negative consequences associated with broad TGFinhibitionSynthis
has generated a T cell targeted TGFantagonistT Ato selectively reverse TGFmediated immune
suppression and restore mediated tumor clearanceIn this Phase SBIR grantwe will determine the efficacy of T A in combination with anti PDagainst
melanoma tumors in vitro and in vivoIn Specific AimT AantiPDwill be tested for their ability to restore
immune mediated tumor cell killing in the presence of TGFwith corresponding effector function analysisi etumor specific T cell expansionTo investigate potential adverse eventsthe levels of several proinflammatory cytokinessuch as TNFILand ILwill be measured following treatmentIn Specific AimT A will be tested in an in vivo human patient derived xenograftPDXmelanoma model for tumor regression
and corresponding intratumoral immune infiltratesA successful outcome is afold increase in tumor cell
cytotoxicity compared to untreated cells in vitro and afold increase in tumor infiltrating immune cells ortumor regression in vivoThese studies validate the feasibility of developing a T A as an IO therapy and are
the prerequisite for pursuing combination in vivo PDX studies with checkpoint inhibitors in Phase IIVirtually every tumor typeincluding melanomahas increased TGFlevelswhich correlates with
worse prognosisAdvanced melanoma is our first indication since many patients fail immune checkpoint
blockade and new options are required to address this unmet needWith nearlynew melanoma cases
annuallythe melanoma market is forecasted to be $billion bywith the immune checkpoint inhibitors
accounting for $billionT A will provide new treatment options for melanoma patients in combination with
immune checkpoint inhibitors as well as for refractory relapsed patient populations SBIR PHASE I PROJECT NARRATIVE
Synthis is an early stage biotech company focused on developing innovative immune oncology therapeutics to
treat advanced melanoma patientsIn this Phase I SBIRSynthis is developing a proprietary antibody drug
conjugateADCthat reverses immune suppression and restores tumor clearance in melanoma patients

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government